| 09/18/2026 4:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/18/2026 4:20 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 09/18/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 09/17/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 09/09/2026 5:09 PM | Conduit Pharmaceuticals (1896212) Subject Wigglesworth Craig Stuart (2154266) Filed by | Form SCHEDULE 13G | |
| 09/08/2026 4:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
| 09/04/2026 3:05 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/02/2026 5:10 PM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 09/02/2026 5:12 PM | Conduit Pharmaceuticals (1896212) Issuer Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/02/2026 5:16 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13G | |
| 09/01/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for CDTTW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/01/2026 7:00 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/21/2026 4:26 PM | Conduit Pharmaceuticals (1896212) Subject Primary Development Fund (0) Cayman | Form SCHEDULE 13G | |
| 08/21/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Subject Primary Development Fund (0) Cayman | Form SCHEDULE 13G | |
| 08/21/2026 8:27 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K/A | |
| 08/21/2026 8:27 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K/A | |
| 08/12/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/12/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form DEFA14A | |
| 08/11/2026 7:45 AM | Conduit Pharmaceuticals (1896212) Filer | Form DEF 14A | |
| 08/11/2026 7:49 AM | Conduit Pharmaceuticals (1896212) Filer | Form ARS | |
| 07/31/2026 4:26 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2026 4:29 PM | Conduit Pharmaceuticals (1896212) Filer | Form PRE 14A | |
| 07/16/2026 7:05 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/15/2026 3:46 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/07/2026 4:20 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/29/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/23/2026 5:40 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 5:42 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13D/A | |
| 06/16/2026 4:00 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2026 7:51 PM | Ascent Partners Fund LLC (2059960) Filed by Conduit Pharmaceuticals (1896212) Subject | Form SCHEDULE 13G | |
| 05/20/2026 6:03 PM | Conduit Pharmaceuticals (1896212) Subject Nirland Ltd (1994188) Filed by | Form SCHEDULE 13G | |
| 05/14/2026 7:42 AM | Conduit Pharmaceuticals (1896212) Issuer Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 7:47 AM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 05/03/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 05/01/2026 4:11 PM | Conduit Pharmaceuticals (1896212) Filer | Form 424B3 | |
| 04/30/2026 7:16 PM | Conduit Pharmaceuticals (1896212) Issuer Olsen Ulrik K (2132215) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 04/21/2026 8:56 PM | Conduit Pharmaceuticals (1896212) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 04/15/2026 4:01 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/30/2026 8:21 PM | Conduit Pharmaceuticals (1896212) Subject Taylor Mark Andrew (2119432) Filed by | Form SCHEDULE 13D | |
| 03/30/2026 8:22 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting Taylor Mark Andrew (2119432) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/30/2026 8:23 PM | Conduit Pharmaceuticals (1896212) Issuer Prospect Capital Securities Ltd (2120744) Reporting Prospect Capital Securities Ltd (2120744) Reporting Prospect Finance Ltd (2120961) Reporting Taylor Mark Andrew (2119432) Reporting Taylor Mark Andrew (2119432) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Why I believe the AI market will split in Q4 (Ad) Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon.
One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance.
See the full breakdown in his Great AI Shock briefing. Watch the free briefing on the AI market split now |
| 03/25/2026 7:15 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/18/2026 3:53 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/06/2026 3:12 PM | Conduit Pharmaceuticals (1896212) Filer | Form DEF 14A | |
| 02/24/2026 3:53 PM | Conduit Pharmaceuticals (1896212) Filer | Form PRE 14A | |
| 02/23/2026 7:27 PM | Conduit Pharmaceuticals (1896212) Issuer Farley Chele Chiavacci (1908750) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/18/2026 5:26 PM | Ascent Partners Fund LLC (2059960) Filed by Conduit Pharmaceuticals (1896212) Subject | Form SCHEDULE 13G | |
| 02/09/2026 11:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form EFFECT | |
| 01/30/2026 8:06 AM | Conduit Pharmaceuticals (1896212) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 01/22/2026 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/02/2026 3:30 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/22/2025 3:05 PM | Conduit Pharmaceuticals (1896212) Subject Corvus Capital Ltd. (1990829) Filed by | Form SCHEDULE 13D/A | |
| 12/22/2025 3:05 PM | Conduit Pharmaceuticals (1896212) Issuer Corvus Capital Ltd. (1990829) Reporting Regan Andrew (1991325) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/12/2025 3:15 PM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/13/2025 3:46 PM | Conduit Pharmaceuticals (1896212) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/09/2025 7:15 AM | Conduit Pharmaceuticals (1896212) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |